navify Cervical Screening is designed to scale up organized screening programs, increase adherence to recommended clinical guidelines, reduce under- and over-testing and optimize healthcare resources through two unique components.
navify® Cervical Screening
Empowering healthcare systems to move from opportunistic to organized cervical cancer screening.
Digitizes tasks along the patient journey and enables up to 15x faster action on abnormal results.¹* Standardizes screening pathways to improve patient care decisions.
Population Analytics for program managers
Monitors the performance of screening programs. Identifies areas to improve population care.
Aggregated view of all patients
A home screen to summarize the screening status of all patients
Options for clinicians to search for patients by name or ID
Next steps based on the risk of patients developing cervical cancer and grouped into categories: abnormal results, no abnormal results, awaiting next steps, pending results and inadequate samples
Overdue actions are color-coded in red to help increase turnaround time
Patient lists sorted by priority
Details about the current and next screening step for the patient and their due dates
Filters to sort patients based on priority, so the most urgent cases get handled first
Overdue patients flagged in red to reduce loss to follow-up
A contact log for clinicians to document and keep an audit of patient communication
A full patient screening history
A patient dashboard to track their medical records and current screening status
Automated lab communication to ensure patient test results flow seamlessly into the tool
Graphical screening pathways to visualize decision-making and follow-up actions
A form with diagrams to document colposcopy procedures in a precise and consistent way
Population Analytics
Dashboards with exportable reports
An overview of key metrics to achieve program goals with more than 60 graphical performance metrics
Filters by medical site, lab, age, date and screening strategy
Exportable reports to demonstrate program performance in real-time and show progress toward the WHO 90–70–90 goals2
Screening and diagnostic test results
A testing results dashboard to analyze results from different testing technologies like HPV, cytology and biopsies, along with historical trends and correlations between tests
Quality metrics for key areas of the testing journey
A time to diagnosis dashboard to monitor program length and which steps are not meeting targets
Details into population groups
A patient attendance dashboard to analyze screening coverage and dropout rates across different steps of the screening process
A population overview dashboard to monitor key metrics (e.g. HPV positivity and dropout rates) via a map view of the different centers
Digitalization emerges as a strategic advantage in the public sector. It allows us to do better with what we have, reaching more individuals and making every resource count in our fight against cervical cancer.
Comprehensive patient and program management
Streamline patient journeys and improve adherence to guidelines with Patient Tracker. Monitor program performance and optimize resources with Population Analytics
Demonstrated economic benefits
A health economic impact model developed for navify Cervical Screening quantifies the financial and medical benefits of the solution. In Cataluña, Spain, the model highlights*:
Up to 39% annual savings in cancer treatments averted
Up to 17% savings in screening processes through avoidance of under- and over-testing
Up to 49% reduction in costs from unwarranted colposcopies avoided
Total annual cost savings in cervical cancer management of approximately €2.5 million
39%annual saving
in cancer treatments averted.
Organized patient management
Patient Tracker centralizes and organizes patient medical records, lab results and screening pathways to empower clinicians to make better, timely decisions for patients. Insights from a clinical simulation study in Brazil show that clinicians using navify Cervical Screening were at least 49% more likely to adhere to clinical guidelines and 15x faster on average (1 min vs. 15 mins) to act on abnormal results compared to their current clinical practice.1
Data-driven program management
Population Analytics consolidates data across healthcare settings to unlock insights that help sustainably scale up screening programs and improve screening quality – thereby assisting program managers in reducing the disease and the burden on public health. It allows health systems to report screening performance in real-time, optimize spending by highlighting areas for improvement and track progress against the WHO 90–70–90 cervical cancer elimination targets.2
FAQs
Frequently asked questions about navify Cervical Screening
If you don’t find answers to your questions here, we’re happy to provide more information and discuss your needs in detail.
How does navify Cervical Screening support the World Health Organization's elimination goals?
navify Cervical Screening aligns with the WHO's global call to action to eliminate cervical cancer by supporting healthcare systems and countries to advance and scale up organized screening. Organized cervical cancer screening programs are considered a "best buy intervention" and are recommended by the WHO for inclusion in national health plans.2
Why should digital tools, like navify Cervical Screening, be considered for screening programs?
The use of digital technologies can improve the effectiveness and efficiency of screening, promote accountability and facilitate patient access to cervical cancer services.2
How secure is navify Cervical Screening?
At Roche, we take security very seriously. navify Cervical Screening is using cloud infrastructure for navify Platform to deploy different components. This infrastructure is certified ISO 27001, ISO 27017, ISO 27018 and ISO 27701.
What other products does Roche have for cervical cancer?
Roche provides healthcare systems with comprehensive solutions to manage the end-to-end patient journey through screening, triage and diagnosis. The Roche cervical cancer portfolio includes cobas® HPV, a pioneering HPV DNA screening test used in over 55 countries for over a decade; CINtec® PLUS Cytology, which triages women and people with a cervix who are positive for high-risk HPV to determine who would benefit from immediate clinical intervention; and CINtec® Histology, which diagnoses cervical precancer. The portfolio also includes clinician- and self-collection solutions and automated pre-analytical processing and is integrated with the cobas Molecular Work Area Systems and Ventana Benchmark Pathology Work Area systems. By expanding the portfolio with navify Cervical Screening, we aim to help countries and healthcare systems further integrate and scale up screening programs to better protect women.
At Roche Diagnostics, we understand the need to go beyond our products and see the bigger picture, creating a world where product and services come together. Roche Service Solutions refers to our service offering and encompasses our full service portfolio. Our total solution package means we can provide you with the personalised mix of products and services you need. Our digital services enable you to quickly connect with us and help make your life more manageable.
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/9789240014107. Accessed Sep 1, 2023.
Disclaimer
Not every digital product is available in all markets. The use of any third-party app is subject to a separate license agreement with the respective third-party app developer. Roche gives no warranties (express or implied) with regard to any third-party app. Third-party apps might not be available in your country. This website and its content may be accessible worldwide, Roche assumes no liability with regard to the access to the information, which may not be compatible with legislations or regulations in force in your country.
*Results are from a study and may not be reflective of findings at all laboratories.